New insider activity at Medpace Holdings ( (MEDP) ) has taken place on November 24, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CEO August J. Troendle recently sold 28,688 shares of Medpace Holdings stock, amounting to a significant transaction worth $17,031,557.
Recent Updates on MEDP stock
In the last 24 hours, Medpace Holdings has been in the spotlight due to several updates on its ongoing clinical studies, which could influence its stock performance. BMO Capital initiated coverage with a Market Perform rating, citing the stock’s full valuation amid a “tepid” biotech funding environment and potential macroeconomic volatility. Medpace’s collaboration with AVM Biotechnology on the OPAL Study for lymphoid malignancies and a study on ARDS treatment could boost investor confidence if successful, given the potential for new therapeutic options. Additionally, Medpace’s partnerships with Telix Pharmaceuticals and Radiopharm Theranostics on studies for advanced kidney cancer and solid tumors, respectively, highlight its strategic positioning in oncology. These developments underscore Medpace’s focus on advancing cancer treatment innovations, which may positively impact its market perception.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 76.79%
Average Trading Volume: 307,524
Technical Sentiment Signal: Buy
Current Market Cap: $16.67B